BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

  November 26, 2025

   · 

  1 min read
• Press Releases

  Oncology Molecular Diagnostic Market Size Worth USD 8.50 Bn by 2034

  November 26, 2025

   · 

  1 min read
• Press Releases

  Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

  November 26, 2025

   · 

  9 min read
• Press Releases

  Lighthouse Pharmaceuticals To Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025

  November 26, 2025

   · 

  2 min read
• Press Releases

  U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

  November 26, 2025

   · 

  7 min read
• 

  Approvals

  AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer

  Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

  November 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  Novo’s GLP-1s Highlight List as CMS Unveils Final Prices For Second Cycle of Drug Negotiations

  The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the true impact of the negotiations, BMO Capital Markets analysts said.

  November 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Otsuka Secures IgAN Win as FDA Approves First Anti-APRIL Antibody

  Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared with previous accelerated approvals for IgA nephropathy.

  November 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Optimi Health to Supply MDMA to MAPS Israel’s Clinical Trial for Trauma-Related PTSD

  Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSD

  November 26, 2025

   · 

  6 min read
• Press Releases

  PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement

  NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

  November 26, 2025

   · 

  4 min read